L3VLUP
ProSign in

MDLN · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MDLNLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MDLN
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterMDLNLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 2021none listed holders, n.a.31 holders, $29.9bn
Q4 2021none listed holders, n.a.31 holders, $34.7bn
Q1 2022none listed holders, n.a.24 holders, $35.3bn
Q2 2022none listed holders, n.a.33 holders, $42.7bn
Q3 2022none listed holders, n.a.31 holders, $43.4bn
Q4 2022none listed holders, n.a.31 holders, $46.6bn
Q1 2023none listed holders, n.a.33 holders, $44.3bn
Q2 2023none listed holders, n.a.37 holders, $59.6bn
Q3 2023none listed holders, n.a.44 holders, $67.6bn
Q4 2023none listed holders, n.a.45 holders, $73.6bn
Q1 2024none listed holders, n.a.41 holders, $95.3bn
Q2 2024none listed holders, n.a.43 holders, $110bn
Q3 2024none listed holders, n.a.45 holders, $107bn
Q4 2024none listed holders, n.a.46 holders, $93.9bn
Q1 2025none listed holders, n.a.42 holders, $98.4bn
Q2 2025none listed holders, n.a.43 holders, $93.2bn
Q3 2025none listed holders, n.a.39 holders, $86.7bn
Q4 202528 holders, $5.5bn41 holders, $123bn
Q1 202628 holders, $7.9bn39 holders, $106bn
Q2 202621 holders, $9.1bn44 holders, $132bn
MDLN

Medline Inc

Holders
21
Reported value
$9.1bn
Buyers
22
Sellers
23

Breadth -1 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
44
Reported value
$132bn
Buyers
24
Sellers
24

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 54 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MDLN (10)

Baillie Gifford & Co, Davidson Kempner Capital Management LP, Durable Capital Partners LP, Egerton Capital UK LLP, Element Capital Management LLC, Lone Pine Capital LLC, PDT Partners LLC, Verition Fund Management LLC, Viking Global Investors LP, Winton Group Ltd

Only LLY (33)

Acadian Asset Management LLC, AQR Capital Management LLC, ARK Investment Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Discovery Capital Management LLC, Dodge & Cox, Freestone Grove Partners LP, GAMCO Investors Inc, Glenview Capital Management LLC, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Jane Street Group LLC, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Polen Capital Management LLC, Quantbot Technologies LP, and 8 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →